一种新型伤寒Vi多糖疫苗——Vax-TyVi——在古巴学童和青少年中的免疫原性。
Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers.
作者信息
Azze Rolando Felipe Ochoa, Rodríguez Juan Carlos Martínez, Iniesta Mónica Ginebra, Marchena Xenia Rosa Ferriol, Alfonso Vivian María Rodríguez, Padrón Franklin Tomás Sotolongo
机构信息
Instituto Finlay, DACTA, Avenida 27 No. 19805, La Lisa, AP 16017, CP 11600 Ciudad de La Habana, Cuba.
出版信息
Vaccine. 2003 Jun 20;21(21-22):2758-60. doi: 10.1016/s0264-410x(03)00177-4.
A randomized, controlled, double blind study was carried out in Cuban children and teenagers aged 9-13 years to evaluate the immunogenicity of vax-TyVi-Salmonella Typhi Vi polysaccharide vaccine-with respect control vaccines. Serum samples were taken before and 21 days after the immunization, and ELISA was used for the determination of antibodies to Vi polysaccharide. Subjects who received vax-TyVi and TYPHIM Vi (Pasteur-Mérieux) showed seroconversion rates of 85.61 and 78.36%, respectively. The geometric mean titer (GMT) values for Vi antibodies induced after vaccination were 6.27 microg/ml (5.40-7.38 microg/ml) and 5.97 microg/ml (5.01-7.10 microg/ml), respectively. In contrast, subjects receiving the tetanus toxoid vaccine showed 0% seroconversion.
在古巴9至13岁的儿童和青少年中开展了一项随机、对照、双盲研究，以评估伤寒Vi多糖疫苗（vax-TyVi）相对于对照疫苗的免疫原性。在免疫接种前和接种后21天采集血清样本，并采用酶联免疫吸附测定（ELISA）法测定Vi多糖抗体。接种vax-TyVi和TYPHIM Vi（巴斯德-梅里厄公司生产）的受试者血清转化率分别为85.61%和78.36%。接种疫苗后诱导产生的Vi抗体几何平均滴度（GMT）值分别为6.27微克/毫升（5.40 - 7.38微克/毫升）和5.97微克/毫升（5.01 - 7.10微克/毫升）。相比之下，接种破伤风类毒素疫苗受试者的血清转化率为0%。
Zotero 插件